MGF
Aeterna does not sell peptides. External link, vendor independently verified.
Mechanism
Mechano Growth Factor is not a systemic hormone. It is a tissue-specific distress signal – a splice variant of the IGF-1 gene that the body produces in direct response to mechanical damage or metabolic stress. Where systemic IGF-1 circulates broadly, MGF speaks in a narrower register: to the injured site, at the moment of injury, in the language of cellular urgency. Understanding its mechanism requires understanding that distinction first.
Alternative splicing of the IGF-1 gene follows mechanical overload and hypoxic stress, producing the MGF isoform through a distinctive 24-amino-acid E-peptide. This sequence is absent from systemic IGF-1Ea and marks MGF as a structurally distinct local repair signal.
Satellite cell activation is the primary biological effect. Quiescent myogenic precursors enter proliferation, expanding the pool of cells available for repair before differentiation begins.
IGF-1 receptor signaling engages the PI3K–Akt–mTOR axis and supports protein synthesis through the mature IGF-1 domain. This occurs alongside E-domain-associated satellite cell expansion, making the two actions complementary rather than sequential.
Tissue repair signaling is not confined to skeletal muscle. Cardiac and neuronal tissues also upregulate the isoform after ischemic or mechanical insult, suggesting a broader role in injury response biology.
What we observe
Observed muscle recovery changes
The outcomes attributed to MGF derive primarily from in vitro and rodent studies, with limited data in larger animal systems. Human trials are absent as of early 2026. What follows describes patterns investigators have reported under controlled conditions, not outcomes any individual should expect.
01
Satellite Cell Recruitment
02
Myofiber Hypertrophy
03
Accelerated Repair Kinetics
04
Cardiac Cytoprotection
05
Neuronal Survival Signaling
06
Attenuation of Age-Related Atrophy
Evidence
The data behind MGF
The MGF evidence base is predominantly preclinical. The studies cited here represent the most foundational and frequently referenced work in the field. They are offered as a map of what has been investigated, not as proof of clinical efficacy.
Mechano Growth Factor: a putative product of IGF-1 gene expression involved in tissue repair and adaptation
Goldspink and colleagues characterised the temporal expression pattern of MGF in mechanically overloaded rat muscle, demonstrating that MGF mRNA peaks within hours of mechanical stimulus – well before systemic IGF-1Ea rises – and that this early pulse correlates with satellite cell entry into the cell cycle. The study established the foundational model of MGF as a local, rapid-response isoform distinct in timing and tissue distribution from its systemic counterpart.
The E-domain of mechano growth factor inhibits terminal differentiation and enhances proliferation of myoblasts in culture
Using synthetic MGF E-domain peptide in C2C12 myoblast cultures, investigators demonstrated that the E-domain alone – independent of the IGF-1 domain – was sufficient to drive proliferation and delay terminal differentiation. Blocking IGF-1R did not abolish this effect, suggesting a receptor mechanism distinct from classical IGF-1 signaling. The findings positioned the E-domain as a functionally autonomous proliferative signal and informed subsequent interest in PEGylated E-domain analogues.
Local expression of mechano growth factor following experimental myocardial infarction reduces cardiomyocyte apoptosis and infarct size in the rat
Following surgically induced left anterior descending artery occlusion in rats, intramyocardial delivery of MGF plasmid construct resulted in measurably reduced TUNEL-positive cardiomyocytes and a smaller infarct zone at 72 hours compared to empty-vector controls. Akt phosphorylation was elevated in MGF-treated tissue, consistent with activation of the PI3K–Akt survival pathway. The authors noted that the therapeutic window appeared narrow and that delivery timing relative to ischaemic onset was a critical variable.
From lyophilized powder to a usable solution.
Peptide
5 mg lyophilized powder
Diluent
3.0 mL bacteriostatic water
Final concentration
1.67 mg/mL
01
Prepare the vial
02
Draw the diluent
03
Add slowly
04
Prepare the vial
Note
Dosing rythm
A patient titration
Schedule below mirrors the peptidedosages.com educational protocol (typical daily range: 100–300 mcg once daily (gradual titration)).
Storage, caution, contradiction
Storage
Cold, dark, undisturbed
- Lyophilized: freeze at −20 °C (−4 °F).
- After reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F).
- Use within ~30 days.
- Use amber or opaque vials where possible; UV exposure accelerates degradation of the E-domain peptide bond.
- Discard any vial showing particulate matter, cloudiness, or colour change; do not use degraded solution.
Side effects
What members describe
- Injection-site discomfort, transient swelling, or localised erythema - the most commonly reported effects in research subjects receiving intramuscular administration.
- Transient hypoglycaemia is theoretically possible given IGF-1R agonism; monitoring of blood glucose is prudent in susceptible individuals.
- Water retention and soft-tissue oedema have been anecdotally reported, consistent with IGF-1 pathway activation and sodium retention mechanisms.
- Fatigue or lethargy in the hours following administration has been noted in some self-reported accounts; mechanistic basis is unclear.
- Theoretical proliferative risk: as with all IGF-1 pathway agonists, the question of whether MGF could stimulate pre-existing neoplastic cells is raised in the literature and has not been resolved in long-term studies.
Contradictions
Reasons to abstain
- Active or suspected malignancy: IGF-1 pathway activation is a theoretical concern in oncological contexts; use is contraindicated in research protocols involving subjects with known neoplastic disease.
- Pregnancy and lactation: no safety data exist; use is not studied in these populations and is not appropriate.
- Diabetic retinopathy or proliferative retinal disease: IGF-1R agonism has been associated with retinal neovascularisation; caution is warranted.
- Acromegaly or conditions of IGF-1 excess: additive pathway stimulation in the context of existing IGF-1 dysregulation is not studied and is not advisable.
- Concurrent use of insulin or insulin secretagogues without glucose monitoring: the additive hypoglycaemic potential of IGF-1R agonism warrants careful oversight.
Synergies
Best partners for MGF
MGF is rarely studied in isolation in the self-experimentation literature, though formal combination studies are absent. The pairings below reflect mechanistic logic – where one peptide’s temporal window complements another’s – rather than clinical evidence. Aeterna does not prescribe combinations. These are educational observations.
FAQ
Your questions, patiently answered
The distinction is primarily one of origin, timing, and tissue specificity. MGF is produced locally at the site of mechanical damage, peaks within hours, and carries a unique E-domain that appears to act through a receptor mechanism independent of IGF-1R. IGF-1 LR3 is a synthetic long-acting analogue of systemic IGF-1, designed for sustained IGF-1R engagement across tissues. MGF is a local, transient, damage-responsive signal; IGF-1 LR3 is a prolonged, systemic anabolic signal. They are not interchangeable.
Native MGF is rapidly degraded by serum proteases – particularly those targeting the E-domain peptide sequence. In vivo, this brevity is likely functional: a local repair signal that persists systemically would lose its tissue-specificity. PEGylation of the E-domain extends the half-life to several hours by sterically hindering protease access, at the cost of altering the native pharmacokinetic profile. Whether the PEGylated analogue fully recapitulates native MGF biology is not established.
As of 2026, no controlled human clinical trials have been published for MGF or its PEGylated analogue. The evidence base is composed of in vitro cell studies, rodent models, and a small number of larger animal experiments. Self-reported human use exists in the grey literature but does not constitute evidence. This is a compound whose human pharmacology remains substantially unknown.
The literature documents MGF expression and apparent activity in cardiac tissue following ischaemic injury and in neuronal populations under hypoxic stress. In both contexts, cytoprotective effects have been observed in preclinical models – reduced apoptosis, improved cellular survival. These findings are preliminary and have not been translated into clinical applications. They do, however, suggest that MGF’s biology extends beyond the musculoskeletal system.
The E-domain is the 24-amino-acid C-terminal extension unique to the MGF splice variant. Research using synthetic E-domain peptide – administered without the IGF-1 domain – has demonstrated proliferative effects on myoblasts that are not abolished by IGF-1R blockade, suggesting the E-domain engages a distinct receptor or signaling mechanism. The identity of this receptor has not been definitively established. The E-domain is therefore both a structural marker of MGF identity and a functionally autonomous signaling element.
The literature documents a measurable decline in the MGF response to mechanical loading with advancing age – a pattern that correlates with the well-characterised reduction in satellite cell responsiveness seen in sarcopenia. Whether this decline is causal or correlative in the sarcopenia process is not resolved. It has, however, generated interest in MGF as a potential tool for studying – and potentially addressing – age-related muscle loss, an area where preclinical results are suggestive but human evidence is absent.
In the same family
Further reading in the curriculum.
Sourcing · Independently verified
When you're ready, source thoughtfully.